北京中银（深圳）律师事务所 关于深圳市海普瑞药业集团股份有限公司 2024 年年度股东大会的 法律意见书 地址：深圳市福田区益田路 6003 号荣超商务中心 A 座 5、6 层 电话：（86-755）82531588 传真：（86-755）82531555 邮编：518026 北京中银（深圳）律师事务所 法律意见书 北京中银（深圳）律师事务所 关于深圳市海普瑞药业集团股份有限公司 2024 年年度股东大会的 法律意见书 致：深圳市海普瑞药业集团股份有限公司 北京中银（深圳）律师事务所（以下简称"本所"）接受深圳市海普瑞药业集 团股份有限公司（以下简称"公司"）委托，就公司召开 2024 年年度股东大会（以 下简称"本次股东大会"）的有关事宜，根据《中华人民共和国公司法》（以下简 称《公司法》）《上市公司股东大会规则》等法律、法规、规章和其他规范性文 件以及《深圳市海普瑞药业集团股份有限公司章程》（以下简称《公司章程》） 的有关规定，出具本法律意见书。 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行 了法定职责，遵循了勤 ...

深圳市海普瑞药业集团股份有限公司 证券代码：002399 证券简称：海普瑞 公告编号：2025-025 2024年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决提案的情形； 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开情况 1、会议召开时间： （1）现场会议时间：2025年5月22日下午14:00 3、会议召开方式：现场表决与网络投票相结合的方式 4、会议召集人：公司第六届董事会 5、会议主持人：董事长李锂 6、召开会议的通知已于2025年3月29日刊登在《证券时报》《中国证券报》 《上海证券报》《证券日报》及巨潮资讯网（www.cninfo.com.cn）上（2025-009）。 本次股东大会的召集及召开符合《中华人民共和国公司法》《上市公司股东 会规则》《深圳证券交易所股票上市规则》等法律法规、规范性文件及《深圳市 海普瑞药业集团股份有限公司章程》的有关规定。 二、会议出席情况 1、股东出席情况 （2）网络投票时间：2025年5月22日 公司A股股东通过深圳证券交易所交易系 ...

Financial Performance - In 2024, the Company reported revenue of RMB 5,258,919, a decrease of 3.2% compared to RMB 5,430,974 in 2023[15] - The profit before tax for 2024 was RMB 726,229, recovering from a loss of RMB 928,334 in 2023[15] - The profit attributable to owners of the Company for 2024 was RMB 646,742, compared to a loss of RMB 783,258 in 2023[15] - Basic earnings per share for 2024 was RMB 0.44, an improvement from a loss of RMB 0.53 in 2023[15] - The Group achieved a revenue of approximately RMB5,258.9 million and a net profit of approximately RMB624.9 million, marking significant year-on-year growth[27] - The Group achieved an operating revenue of approximately RMB5,258.9 million in 2024, representing a year-on-year decrease of approximately 3.2%[49] - Gross profit increased by approximately 84.9% year-on-year to approximately RMB1,739.3 million, with a gross margin of approximately 33.1%, up by approximately 15.8 percentage points year-on-year[49] - The Group turned from loss into profit, reporting a net profit of approximately RMB624.9 million, with net profit attributable to equity holders of the Company at approximately RMB646.7 million[49] - The Group's overall operating revenue was approximately RMB5,258.9 million, a year-on-year decrease of approximately 3.2%, while gross profit increased by approximately 84.9% to RMB1,739.3 million, with a gross margin of approximately 33.1%[52] - The impairment amount for inventory in 2024 was only approximately RMB7.6 million, significantly lower than RMB855.4 million in 2023, contributing to improved gross profit margins[102] - Finance costs decreased by approximately RMB82.9 million to approximately RMB145.2 million, representing a decrease of approximately 36.3% compared to 2023[106] - Income tax expense for the reporting period was approximately RMB 101.3 million, compared to a tax credit of approximately RMB 126.2 million in 2023[111] Assets and Liabilities - Total assets decreased to RMB 17,343,524 in 2024 from RMB 19,203,417 in 2023, reflecting a decline of 9.7%[16] - Total liabilities also decreased to RMB 5,141,403 in 2024, down from RMB 7,215,040 in 2023, a reduction of 28.8%[16] - The asset-liability ratio was approximately 29.6% as of December 31, 2024, down from approximately 37.6% in 2023[127] - As of December 31, 2024, the group's cash and bank balances were approximately RMB 1,421.8 million, down from approximately RMB 1,765.6 million in 2023[118] - The group recorded short-term loans of approximately RMB 2,367.2 million and long-term loans of approximately RMB 1,081.0 million as of December 31, 2024[119] - The Group's total financial indebtedness decreased to approximately RMB3,544.8 million from RMB5,562.8 million as of December 31, 2023, representing a reduction of about 36.4%[140] - The Group's interest-bearing bank and other borrowings were approximately RMB3,448.2 million as of December 31, 2024, down from RMB5,434.6 million in the previous year, indicating a decrease of approximately 36.5%[140] - The Group's lease liabilities decreased to RMB96.6 million as of December 31, 2024, from RMB128.2 million as of December 31, 2023, a reduction of about 24.6%[140] Business Strategy and Operations - The Company emphasized its commitment to innovation-driven and globalization strategies, enhancing its global marketing network[24] - The Company aims to consolidate its leading position in the international heparin market through a vertically integrated industry chain[24] - The Company has transformed from a local enterprise to a global leader in the heparin field over the past decade[24] - The heparin business, as the core pillar, set a historical best performance with a significant leap in market share due to enhanced local operations and market penetration[28] - The CDMO business exhibited strong growth, forming a "dual-wheel drive" development pattern, enhancing market competitiveness and overall performance[29] - The Group plans to further optimize the vertical integration of the heparin industry chain to enhance product competitiveness and market share[37] - The Group aims to accelerate the clinical progress of the H1710 project and explore more opportunities for innovative drug research and development[37] - The Group will strengthen the diversified operations of SPL and Cytovance to promote sustained growth in CDMO and specialty product businesses[37] - The Group remains cautiously optimistic about its business prospects while focusing on cost control to ensure stable financial benefits and cash flow levels[38] - The Group plans to further optimize the heparin supply chain's vertical integration to enhance product competitiveness and market share[40] - The CDMO business experienced rapid growth during the Reporting Period, with both business revenue and gross margin increasing year-on-year[48] - The Group aims to enhance its global presence and brand influence while increasing market penetration in the heparin industry despite trade protectionist challenges[82] - The Group plans to optimize marketing strategies and improve sales share in the finished dosage form business, targeting growth in Asia-Pacific and Latin America[84] Research and Development - The innovative drug H1710 project completed its IND application in China, marking a breakthrough in the Group's innovation efforts[30] - H1710, a candidate drug targeting heparanase, has shown significant anti-tumor effects in various animal models and received approval for clinical trials from the National Medical Products Administration in February 2025[73] - Oregovomab, an anti-CA125 immunotherapy drug, completed a Phase II clinical trial and is under further evaluation after not meeting its intended objectives in Phase III trials[74] - RVX-208 (Apabetalone) completed Phase III clinical trial (BETonMACE) to reduce major adverse cardiovascular events in high-risk patients, receiving FDA Breakthrough Therapy Designation[79] - The Group is actively exploring cooperation opportunities to accelerate the strategic layout of innovative drugs and diversify commercialization capabilities[76] Market Performance - The annual sales volume of enoxaparin sodium formulations achieved double-digit growth, successfully expanding the global formulation market share[47] - The Group maintained its market share as one of the top two in Europe for enoxaparin sodium formulation, successfully increasing the bid-winning rate to expand market share[56] - In the United States, the Group's sales revenue showed impressive growth, benefiting from a dual strategy of self-operated and agency-driven approaches[57] - The Group obtained market entry licenses in Thailand and New Zealand, enhancing its international market share and creating new sales opportunities[61] - The Group is actively working to increase market share in China while addressing pricing pressures from the national centralized procurement platform[58] Management and Governance - The Group's executive directors have over 30 years of experience in the pharmaceutical industry, contributing to strategic planning and decision-making[142] - The Group's strategic focus includes innovative drugs and CDMO sectors, with active participation from executive directors in formulating and implementing business strategies[149][152] - The Group's management team includes experienced professionals who oversee various aspects of the business, including production capacity, logistics, and human resources[152][149] - Ms. Li Tan has over 30 years of experience in the pharmaceutical industry and is responsible for major decisions and business development activities[155] - Mr. Shan Yu also has over 30 years of experience in the pharmaceutical industry, overseeing capacity, safety, logistics, and external matters[156] - Mr. Zhang Ping has extensive experience in manufacturing and operations, having served as General Manager at Hangzhou Innovax Biotech Co., Ltd. and Head of Industry Affairs at Sanofi, managing seven plants in China[157][161] - Dr. Lu Chuan has been an independent non-executive director since December 2019 and has extensive experience in investment banking and management[158][162] - Mr. Huang Peng, an independent non-executive director, has a Ph.D. in Management and has served as an independent director for multiple companies listed on the Shanghai and Shenzhen Stock Exchanges[164] - Mr. Yi Ming, another independent non-executive director, has a Master's degree in Finance and has held senior management positions in asset management companies[165] - Mr. Zheng Zehui, chairman of the Supervisory Committee, has served as general manager of URIT Medical Electronic Sales Co., Ltd. and has a background in biochemistry[166] - Ms. Tang Haijun has been with the company since February 2001 and serves as a Supervisor, managing the GXP document control department[167] Corporate Actions - The Company completed its initial public offering and listing of its A Shares on the Shenzhen Stock Exchange on May 6, 2010, and its H Shares on the Hong Kong Stock Exchange on July 8, 2020[181] - The Group proposed a final cash dividend of RMB2.5 (tax inclusive) per ten ordinary shares, compared to nil in 2023[187] - The Group has not incurred any additional costs specifically attributable to environmental compliance during the year ended December 31, 2024[191] - The Group has no current plans for significant acquisitions or capital asset investments as of December 31, 2024[138] Reporting and Analysis - A detailed analysis of the Group's revenue and operating profit for the year ended December 31, 2024, is provided in the "Management Discussion and Analysis" section of the annual report[182] - The business review includes discussions on principal risks and uncertainties faced by the Group, as well as an analysis of performance using financial key performance indicators[183] - Important events affecting the Group during the year ended December 31, 2024, are highlighted in the annual report[183] - Future developments in the Group's business are indicated in the annual report[183] - The Group's financial performance indicators and major events impacting the business are discussed in the "Chairman's Statement" and "Management Discussion and Analysis" sections of the annual report[186] - The Group's audited consolidated results for the reporting period are detailed on pages 85 to 86 of the annual report[188] - The Group's reserves and movements for the current and prior years are presented in the consolidated statement of changes in equity on pages 89 to 90 of the annual report[200]

Core Viewpoint - The recent financial report of Haiprui (002399) shows a year-on-year increase in both revenue and net profit for Q1 2025, indicating stable performance despite some declines in profit margins and cash flow metrics [1]. Financial Performance - Total revenue for Q1 2025 reached 1.394 billion yuan, a 1.53% increase compared to 1.373 billion yuan in Q1 2024 [1]. - The net profit attributable to shareholders was 157 million yuan, reflecting a 1.0% increase from 155 million yuan in the same period last year [1]. - Gross margin decreased to 27.34%, down 20.74% year-on-year, while net margin slightly declined to 11.2%, a decrease of 0.51% [1]. - Total expenses (selling, administrative, and financial) amounted to 135 million yuan, representing 9.66% of revenue, a significant reduction of 45.77% year-on-year [1]. Key Financial Ratios - Earnings per share (EPS) remained stable at 0.11 yuan, with a slight increase of 0.95% year-on-year [1]. - The company's cash flow per share decreased to 0.37 yuan, down 38.21% from 0.60 yuan [1]. - The company's return on invested capital (ROIC) was reported at 4.33%, indicating weak capital returns in recent years [3]. Debt and Cash Flow Analysis - The company has a healthy cash position, with cash assets covering 87.19% of current liabilities [3]. - The interest-bearing debt decreased to 3.544 billion yuan, a reduction of 27.03% compared to the previous year [1]. - Accounts receivable increased to 1.382 billion yuan, a rise of 19.95% year-on-year, raising concerns about collection efficiency as accounts receivable to profit ratio reached 213.74% [3]. Market Dynamics - The company is closely monitoring the market for heparin active pharmaceutical ingredients (API), which are currently priced low, and is focused on maintaining its pricing structure [3].

Core Viewpoint - The company, Shenzhen Hepalink Pharmaceutical Group Co., Ltd., has announced its first-quarter report for 2025, confirming the accuracy and completeness of the financial information disclosed [2][24]. Financial Data - The first-quarter report has not been audited [3][7]. - There are no adjustments or restatements required for previous accounting data [4]. - The company does not have any non-recurring profit and loss items [4]. Shareholder Information - The total number of ordinary shareholders and the situation of the top ten shareholders have been disclosed, with no changes reported in the lending of shares [6]. Board Meeting - The sixth board meeting of the company was held on April 24, 2025, with all seven directors participating and approving the first-quarter report [8][9]. - The board also approved an adjustment to the capital increase plan for its wholly-owned subsidiary, Tian Dao Pharmaceutical (Hong Kong) Co., Ltd., reducing the amount from USD 105 million to USD 31.92 million [11][12]. Subsidiary Capital Increase - The capital increase is aimed at expanding the sales and marketing network in the EU and other global markets [17][18]. - The adjustment to the capital increase plan was made in response to external market conditions and the company's global business development needs [18][22]. Product Approval - The company's subsidiary, Shenzhen Tian Dao Pharmaceutical Co., Ltd., received approval from the South African Health Products Regulatory Authority for its Enoxaparin Sodium Injection [25]. - This approval allows the company to sell its Enoxaparin Sodium products in the South African market, enhancing its global market share [26][28].

证券代码：002399 证券简称：海普瑞 公告编号：2025-023 深圳市海普瑞药业集团股份有限公司 第六届监事会第十一次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、监事会会议召开情况 具体内容详见公司同日披露于《证券时报》《中国证券报》《上海证券报》《证 券日报》和巨潮资讯网www.cninfo.com.cn的《2025年第一季度报告》；及同日披露 于 香 港 联 合 交 易 所 有 限 公 司 网 站 http://www.hkexnews.hk 和 公 司 网 站 http://www.hepalink.com的H股《2025年第一季度业绩公告》。 2、《关于调整向全资子公司天道医药（香港）有限公司增资方案的议案》 表决结果：3票同意、0票弃权、0票反对。 公司于2021年12月10日召开的第五届董事会第十五次会议审议通过，公司决 定使用H股募集资金1.05亿美元以逐层增资的方式向全资子公司天道医药（香港） 有限公司增资，用于欧盟及其他全球市场拓展销售及营销网络以及基础设施的建 设。 根据外部市场环境结合公司全球业务发展的需求，决 ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 1,394,250,050.21, representing a 1.53% increase compared to CNY 1,373,251,921.93 in the same period last year[8] - Net profit attributable to shareholders for Q1 2025 was CNY 156,590,188.54, a 1.00% increase from CNY 155,040,262.39 year-on-year[8] - The net profit after deducting non-recurring gains and losses increased by 20.27% to CNY 188,891,082.26 from CNY 157,052,354.18 in the previous year[8] - The total operating profit for the current period is 178,980,342.21, a decrease of 9.4% from 196,847,737.66 in the previous period[34] - Net profit for the current period is 156,169,189.45, showing a slight increase of 1.0% compared to 154,597,836.94 in the previous period[34] - The company's net profit margin improved, with net profit for the period showing a significant recovery compared to the previous period, although specific figures were not disclosed[33] Cash Flow - The net cash flow from operating activities decreased by 38.21% to CNY 544,031,931.35, down from CNY 880,453,882.15 in the same period last year[8] - The cash flow from operating activities is 544,031,931.35, down 38.3% from 880,453,882.15 in the previous period[39] - The net cash flow from investing activities saw a significant decline of 297.07%, resulting in a negative cash flow of ¥257,551,999.87, mainly due to increased purchases of financial products[19] - The cash flow from investment activities shows a net outflow of 257,551,999.87, compared to a net inflow of 130,688,287.99 in the previous period[40] - The net cash flow from financing activities increased by 103.37% to ¥22,602,544.83, as the amounts borrowed and repaid remained relatively stable compared to the previous year[19] - Net cash flow from financing activities was $22,602,544.83, a significant improvement from a negative $670,833,066.44 in the previous period[41] Assets and Liabilities - Total assets at the end of the reporting period were CNY 17,545,801,889.02, reflecting a 1.17% increase from CNY 17,343,523,964.97 at the end of the previous year[8] - Total liabilities increased to CNY 5,205,766,284.88 from CNY 5,141,403,413.17, reflecting an increase of approximately 1.2%[31] - The equity attributable to shareholders increased by 1.14% to CNY 12,287,013,002.74 from CNY 12,148,672,778.24 year-on-year[8] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 28,367, with the largest shareholder, Shenzhen Lerun Technology Co., Ltd., holding 32.31% of shares[22] - The top ten shareholders collectively hold significant stakes, with the second-largest shareholder, Xiamen Jintian Soil Investment Partnership, holding 27.81%[22] - The largest shareholder, Shenzhen Lerun Technology Co., Ltd., has a total of 474,029,899 shares, while the second-largest holds 408,041,280 shares[23] - The company has not reported any changes in the participation of the top ten shareholders in margin trading or securities lending activities compared to the previous period[24] - There are no preferred shareholders or related changes reported in the current period[24] Investment and Expenses - The company reported a significant increase in investment income, rising by 132.79% to CNY 20,292,064.76 from a loss of CNY 61,890,173.43 in the previous year[17] - Research and development expenses were CNY 39,993,799.57, up from CNY 35,294,968.25, indicating an increase of about 19.2%[33] - The company experienced a 190.08% decrease in financial expenses, resulting in a gain of CNY 56,508,230.69 due to foreign exchange gains[17] - The deferred income increased by 65.95% to CNY 45,279,690.29, primarily due to government subsidies received during the reporting period[15] - The company reported a substantial increase in asset disposal income, which rose by 4404.34% to CNY 1,288,820.50 from CNY 28,612.85 in the previous year[17] Inventory and Receivables - Accounts receivable increased to CNY 1,382,358,370.19 from CNY 1,178,554,557.22, showing a rise of about 17.3%[28] - Inventory decreased to CNY 4,952,734,323.44 from CNY 5,393,947,174.38, a decline of approximately 8.2%[28] Cash and Equivalents - The company's cash and cash equivalents at the end of the period were CNY 2,000,842,827.21, up from CNY 1,689,041,495.34 at the beginning of the period, indicating a growth of approximately 18.4%[28] - The ending balance of cash and cash equivalents was $1,740,464,878.53, down from $2,108,383,601.96 in the prior period[41] - The net increase in cash and cash equivalents was $318,638,044.68, slightly lower than $342,738,890.08 in the previous period[41] Other Financial Metrics - The total comprehensive income for the current period is 137,915,052.34, a decrease of 8.1% from 150,135,056.48 in the previous period[36] - Basic and diluted earnings per share for the current period are both 0.1067, an increase from 0.1057 in the previous period[36] - The company recorded a foreign exchange loss of 47,399,165.67 in other comprehensive income, contrasting with a gain of 3,002,651.97 in the previous period[35] - The company received cash from sales of goods and services totaling 1,327,258,705.88, down 11.1% from 1,493,180,137.55 in the previous period[39] - The company reported a decrease in cash received from other operating activities to 47,510,298.94, down from 97,379,140.23 in the previous period[39] - The company’s net impairment loss on assets decreased significantly to 44,094.91 from 33,754,398.03 in the previous period[34] Audit and Reliability - The first quarter report was not audited, indicating potential limitations in financial reliability[42]

一、主要会计数据和财务指标 三、分红送配方案情况 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.1067 | 0.1057 | 0.95 | 0.0453 | | 每股净资产（元） | 8.37 | 8.22 | 1.82 | 8.43 | | 每股公积金(元) | 4 | 4.33 | -7.62 | 3.99 | | 每股未分配利润(元) | 2.86 | 2.41 | 18.67 | 2.99 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 13.94 | 13.73 | 1.53 | 13.01 | | 净利润(亿元) | 1.57 | 1.55 | 1.29 | 0.67 | | 净资产收益率(%) | 1.28 | 1.29 | -0.78 | 0.54 | 本次公司不分配不转赠。 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 125360.0 ...

Revenue and Profit - The company's revenue for Q1 2025 was ¥1,394,250,050.21, representing a year-over-year increase of 1.53% compared to ¥1,373,251,921.93 in the same period last year[5]. - Net profit attributable to shareholders was ¥156,590,188.54, a slight increase of 1.00% from ¥155,040,262.39 in the previous year[5]. - The net profit after deducting non-recurring gains and losses increased by 20.27% to ¥188,891,082.26 from ¥157,052,354.18 year-over-year[5]. - Total operating revenue for the current period reached ¥1,394,250,050.21, an increase of 1.4% compared to ¥1,373,251,921.93 in the previous period[23]. - Net profit for the current period was ¥156,169,189.45, slightly higher than ¥154,597,836.94 from the previous period, indicating a growth of about 1%[24]. - Earnings per share (EPS) for the current period was ¥0.1067, compared to ¥0.1057 in the previous period, showing an increase of 0.9%[25]. Cash Flow - The net cash flow from operating activities decreased significantly by 38.21% to ¥544,031,931.35 from ¥880,453,882.15 in the same period last year[5]. - Cash inflow from operating activities totaled ¥1,501,965,061.54, a decrease from ¥1,664,646,503.27 in the previous period, representing a decline of approximately 9.7%[26]. - The net cash flow from operating activities was $544,031,931.35, a decrease of 38.2% compared to $880,453,882.15 in the previous period[27]. - Total cash outflow from operating activities amounted to $957,933,130.19, up from $784,192,621.12, indicating a 22.1% increase[27]. - Cash inflow from investment activities totaled $605,376,122.24, compared to $441,112,963.21, reflecting a 37.3% increase[27]. - The net cash flow from investment activities was -$257,551,999.87, a decline from $130,688,287.99 in the previous period[27]. - Cash inflow from financing activities was $750,396,287.53, down from $835,834,333.10, representing a decrease of 10.2%[27]. - The net cash flow from financing activities was $22,602,544.83, a significant improvement from -$670,833,066.44 in the previous period[27]. - The total cash and cash equivalents at the end of the period were $1,740,464,878.53, down from $2,108,383,601.96[27]. - The cash and cash equivalents increased by $318,638,044.68 during the period, compared to an increase of $342,738,890.08 in the previous period[27]. Assets and Liabilities - Total assets at the end of the reporting period were ¥17,545,801,889.02, reflecting a 1.17% increase from ¥17,343,523,964.97 at the end of the previous year[5]. - The company's total liabilities amounted to ¥5,205,766,284.88, compared to ¥5,141,403,413.17 in the previous period, reflecting an increase of about 1.25%[21]. - Total equity attributable to shareholders reached ¥12,287,013,002.74, up from ¥12,148,672,778.24, marking an increase of approximately 1.14%[21]. - Total current assets amount to 9,873,944,183.93 RMB, an increase from 9,621,274,306.15 RMB at the beginning of the period[19]. - Total assets amount to 17,545,801,889.02 RMB, compared to 17,343,523,964.97 RMB at the beginning of the period[20]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 28,367[16]. - The largest shareholder, Shenzhen Lerun Technology Co., Ltd., holds 32.31% of shares, totaling 474,029,899 shares[16]. - The second-largest shareholder, Xiamen Jintian Investment Partnership, holds 27.81%, totaling 408,041,280 shares[16]. Other Financial Metrics - The company's basic earnings per share (EPS) was ¥0.1067, up 0.95% from ¥0.1057 in the same period last year[5]. - The weighted average return on equity (ROE) slightly decreased to 1.28% from 1.29% year-over-year[5]. - The company reported a decrease in financial expenses, with a net financial cost of -¥56,508,230.69 compared to ¥62,732,180.93 in the previous period[24]. - The company experienced a decrease in comprehensive income, totaling ¥137,915,052.34 compared to ¥150,135,056.48 in the previous period, a decline of about 8%[25]. - The company reported a significant increase in deferred income by 65.95% to ¥45,279,690.29 due to government subsidies received during the reporting period[11]. - Deferred income increased to ¥45,279,690.29 from ¥27,284,974.87, indicating a significant rise of approximately 65.9%[21]. - The company has a total of 366,727,264.95 RMB in long-term equity investments[20]. - The company’s goodwill stands at 2,353,689,028.00 RMB, a slight decrease from 2,357,033,547.26 RMB[20]. - Inventory decreased to 4,952,734,323.44 RMB from 5,393,947,174.38 RMB[20]. - Short-term borrowings are reported at 1,819,531,746.74 RMB, slightly down from 1,838,944,224.03 RMB[20]. - The company paid $225,883,127.82 to employees, an increase from $182,063,990.65 in the previous period[27]. - The company reported a total tax payment of $71,329,471.04, up from $61,136,636.42, indicating a 19.8% increase[27].

Core Viewpoint - The approval of Ivenoxin (enoxaparin sodium injection) by the South African Health Products Regulatory Authority is expected to enhance the sales of the product in the South African market and increase the company's global market share [1] Company Summary - The company, Haiprui (002399), announced that its wholly-owned subsidiary, Tiandao Pharmaceutical, has received the approval notification for enoxaparin sodium injection [1] - The product is available in various specifications: 0.2ml:20mg, 0.4ml:40mg, 0.6ml:60mg, 0.8ml:80mg, and 1.0ml:100mg [1] - The indications for the product include thrombosis prevention before and after surgery, reduction of thrombotic risk in acute diseases, and treatment of deep vein thrombosis [1] - The license for the product is valid for five years [1] Industry Summary - The approval is anticipated to boost the company's enoxaparin sodium formulation sales in South Africa, contributing positively to its market presence [1]